Search Results
Evaluating surrogacy endpoints in CLL clinical trials
Use of Surrogate Endpoints in Oncology
Using Surrogate Markers in Clinical Trials for CLL (Chronic Lymphocytic Leukemia)
endpoints, clinical trial outcomes, & surrogate endpoints
Using Surrogate Markers to Determine Efficacy of CLL Treatment - ICML 2023
New endpoints in clinical trials to better serve patients
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 2
Value of MRD measurement in CLL
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 3
MRD in CLL: Clinical Implications
Chronic Lymphocytic Leukemia: MRD Updates